Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice

Leszczyńska, Katarzyna; Namiot, Andrzej; Fein, David E.; Wen, Qi; Namiot, Z; Savage, Paul B.; Diamond, Scott L.; Janmey, Paul A.; Bucki, Robert

doi:10.1186/1471-2180-9-187

Cited by 47 publications

(45 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An in vitro study of CSA-13 susceptibility of seven strains of H. pylori (including clarithromycin and/or metronidazole-resistant strains) indicated MBCs of 0.275-8.9 µg/ml with CSA-13, while MBC values with LL-37 and WLBU2 (an engineered antimicrobial peptide) were 100-800 and 17.8-142 µg/ml, respectively [66].…”

Section: Antibacterial Activitymentioning

confidence: 99%

Ceragenins as Mimics of Endogenous Antimicrobial Peptides

Hashemi¹,

Holden²,

DurnaÅ³

et al. 2017

J Antimicrob Agents

Self Cite

View full text Add to dashboard Cite

Ceragenins are small molecule mimics of endogenous antimicrobial peptides (AMPs), and as such display broadspectrum antimicrobial activity. These molecules are derived from a common bile acid and can be prepared at a large scale. Because ceragenins are not peptide based, they are not substrates for proteases. Gram-negative and positive bacteria are susceptible to ceragenins, including drug resistant organisms. Although ceragenins and colistin have common features, ceragenins retain full antibacterial activity against colistin-resistant Gram-negative bacteria. Bactericidal activity of ceragenins involves selective association with bacterial membranes followed by membrane depolarization. Due to this mechanism of action, which provides bactericidal activity against sessile bacteria, ceragenins eradicate established biofilms. Lipid-enveloped viruses (e.g. vaccinia) are deactivated by ceragenins, and topical application of a lead ceragenin decreases transmission of the virus in skin in a murine model. More recently, the activities of ceragenins against fungal pathogens have been reported, with minimum inhibition concentrations comparable to clinically used anti-fungal agents. In addition to antimicrobial activities, ceragenins have been shown to display some of the "secondary" activities attributed to AMPs. In vivo use of ceragenins to eradicate biofilms, prevent infection and accelerate bone growth demonstrate some of the types of applications in which ceragenins may be used to augment or replace activities of endogenous AMPs.

show abstract

Section: Antibacterial Activitymentioning

confidence: 99%

Ceragenins as Mimics of Endogenous Antimicrobial Peptides

Hashemi¹,

Holden²,

DurnaÅ³

et al. 2017

J Antimicrob Agents

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cathelicidins and defensins are examples of human antimicrobial peptides (AMPs) native to the innate immune system of many eukaryotes that have activity against H. pylori [150] . LL-37 is a cathelicidin with an anti-H. pylori effect [151] , and a recent study demonstrated that cathelicidin limited H. pylori colonization and related gastritis in mouse models [152] . Defensin peptides have also been indicated to impede H. pylori [153] .…”

Section: Eradication: Hope Is Coming?mentioning

confidence: 99%

Antibiotic treatment forHelicobacter pylori: Is the end coming?

Kim

Choi

Chung

2015

WJGPT

View full text Add to dashboard Cite

Infection with the Gram-negative pathogen Helicobacter pylori (H. pylori ) has been associated with gastroduodenal disease and the importance of H. pylori eradication is underscored by its designation as a group I carcinogen. The standard triple therapy consists of a proton pump inhibitor, amoxicillin and clarithromycin, although many other regimens are used, including quadruple, sequential and concomitant therapy regimens supplemented with metronidazole, clarithromycin and levofloxacin. Despite these efforts, current therapeutic regimens lack efficacy in eradication due to antibiotic resistance, drug compliance and antibiotic degradation by the acidic stomach environment. Core tip: This article reviews the recent literature describing antibiotic resistance and trends in Helicobacter pylori (H. pylori ) treatment. As there is no effective conventional therapy, new treatments are being developed and bismuth quadruple, sequential, concomitant therapies are recommended as a first-line regimen in regions with high levels of clarithromycin resistance. Quinolones have also been used for H. pylori treatment, although the cure rate has gradually reduced with this approach. New therapeutic directions include probiotic supplementation, tailored therapy, novel agents, and nanotechnology.

show abstract

“…Dodatnio naładowana cząsteczka CsA-13, naruszając integralność ściany komórkowej mikroorganizmu, wykazuje działanie bakteriobójcze wobec patogenów G(+) i G(-), w tym szczepów bakterii H. pylori opornych na MTZ i/lub CL. Wyniki badań in vitro pokazują, że aktywność przeciwbakteryjna cząsteczki CsA-13 nie zmienia się po preinkubacji w roztworach naśladujących sok żołądko-wy o pH 1,5 z dodatkiem pepsyny lub mucyny [46].…”

Section: Nowe Substancjeunclassified

Treatment prospects of Helicobacter pylori infection

Ksiądzyna¹,

Szandruk²,

Szeląg³

2012

View full text Add to dashboard Cite

Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice

Cited by 47 publications

References 36 publications

Ceragenins as Mimics of Endogenous Antimicrobial Peptides

Ceragenins as Mimics of Endogenous Antimicrobial Peptides

Antibiotic treatment forHelicobacter pylori: Is the end coming?

Treatment prospects of Helicobacter pylori infection

Contact Info

Product

Resources

About